Therapeutic Response

CD20 + status confers therapeutic sensitivity to Carboplatin in combination with Etoposide, Ifosfamide, and Rituximab in patients with Non-Hodgkin Lymphoma.

Statements

Source and description

(R*)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved carboplatin in combination with ifosfamide and etoposide (ICE) for reimbursement as a treatment option for the treatment of relapsed/refractory Non Hodgkin's Lymphoma. The therapy regimen further states that rituximab is to be included for the treatment of CD20 positive patients.